An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery

Trial Profile

An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide
  • Indications Ovarian cancer
  • Focus Pharmacodynamics
  • Sponsors Endocyte
  • Most Recent Events

    • 02 Jun 2017 According to an Endocyte media release, the company plans to stop enrollment in EC1456 trials, where a careful assessment in folate receptor-positive (FR-positive) disease across multiple cohorts of patients and multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement of this agent. However, enrollment of a small number of patients in the this study will continue in order to inform other SMDC programs in development.
    • 26 May 2017 According to an Endocyte media release, preliminary data from the first patient enrolled in this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 16 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top